MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

Biocon to launch most awaited DCGI approved COVID-19 drug Itolizumab; stock jumps five percent

Biocon to launch most awaited DCGI approved COVID-19 drug Itolizumab; stock jumps five percent

Biocon's shares have seen a rapid rise. The stock value has increased to almost five percent on July 14, after the firm announced that it would be launching the most anticipated and awaited biologic drug Itolizumab for the treatment of COVID-19 patients. The drug is priced at Rs. 8000 per vial. Biocon has received approval from the Drugs Controller General of India (DCGI) to market the injection, a 25mg/mL solution for immediate and emergency use in India.

"Itolizumab's unique mechanism of action made it an ideal candidate for treating the 'cytokine storm,' which is a leading cause of death in COVID-19 patients. I am pleased that our R&D and clinical teams delivered on this promising hypothesis in such a short period. It is a proud moment for all of us at Biocon. We want more and more patients to benefit from this therapy," said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon.

The drug will help treat cytokine release syndrome, especially in patients with moderate to acute respiratory distress syndrome (ARDS) due to COVID-19. The drug will be manufactured as an intravenous injection at the bio-manufacturing facility of Biocon Park, Bengaluru. The drug has been approved based on successful and randomized clinical trials at multiple hospitals in Mumbai and New Delhi. The drug also has achieved secondary endpoints and biomarkers, the company said.

YOU MAY ALSO LIKE

Marketing Partnership: NBA, McDonald’s Will Jointly open NBA Experience Zones India

There is good news for all basketball fans in India. Very soon, NBA themed promotions and experience zones will be launched in India. The announcement...

Dunzo to Raise Funds from Google, others

Dunzo, the app which is trying to make life easier for the people upto some extent plans to raise about Rs. 183 crore from different investors which a...

Sapta Shakti Command Will Be Displaying Defence Technology Equipment at Jaipur Military Station

This event is organised with an aim to provide an opportunity where one and all can experience the developments in the field of defence and security-r...

Samsung is All Set to Roll out Its Galaxy A9 Smartphone On November 20

After Samsung unveiled its new Galaxy A9 smartphone in Singapore last month, the company is all set to launch it in India on November 20. In Singapore...

RECOMMENDED